Подписаться
Igor Bondarenko
Igor Bondarenko
Professor of Oncology, Dnipro State Medical University (Ukraine)
Подтвержден адрес электронной почты в домене dmu.edu.ua
Название
Процитировано
Процитировано
Год
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ...
New England Journal of Medicine 364 (26), 2517-2526, 2011
54452011
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...
New England journal of medicine 378 (2), 113-125, 2018
44702018
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
29342019
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
28742019
Fluorouracil leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ...
Journal of clinical oncology 27 (5), 663-671, 2009
21812009
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
21242015
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ...
New England Journal of Medicine 382 (1), 41-50, 2020
21232020
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
20002014
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
17622016
Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ...
New England Journal of Medicine 381 (25), 2391-2402, 2019
17512019
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
15662019
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
15512015
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
G Von Minckwitz, M Procter, E De Azambuja, D Zardavas, M Benyunes, ...
New England Journal of Medicine 377 (2), 122-131, 2017
14742017
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
13862020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 …
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
The Lancet 396 (10265), 1817-1828, 2020
12602020
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ...
New England Journal of Medicine 381 (1), 13-24, 2019
12402019
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
12212011
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind …
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Journal of clinical oncology 30 (17), 2046-2054, 2012
12182012
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ...
New England Journal of Medicine 381 (7), 626-636, 2019
11892019
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised …
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ...
The lancet oncology 15 (2), 143-155, 2014
11002014
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20